Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.59, read 2026-10-27
Ethical passes the values gate
Price74.67 USD
Fair value61.04
Ethical score70.0/100
Our investment reviews on this name
2026-10-21Read Distribution77.11-3.2% to today ✓Markup gives way to Distribution after a 16% slide in 3 weeks
2026-10-02Read Markup92.12-18.9% to today Distribution gives way to Markup after a 38% rise in 8 weeks
2026-08-06Read Distribution66.92+11.6% to today Markup gives way to Distribution after a 21% slide in 5 weeks
2026-07-02Read Markup84.46-11.6% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
MaxLinear, Inc. holds its Distribution at $74.67. The statistical read favours the sellers, held for 132 days.
As held on the ledger · 2026-10-27
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 132 days
Price at the screen
$74.67
Valuation
N/A trailing · 29.51 forward price to earnings
Values screen
PASS· score 70.0
Beta
3.94
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
18.21%
Below 33%
Interest-bearing debt is just 18.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
14.93%
Below 49%
Money owed to the company is 14.9% of assets, under the 49% limit.
Pass
Revenue purity
0.72%
Below 5%
Only 0.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
MaxLinear, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 18%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MXL's ethical verdict changes
Today MXL passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. The price runs 20.8% above the base estimate.
Third-party analyst targets: 11 covering, consensus Buy. The average target sits +34% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chip maker priced for growth it cannot keep
Picture a factory running flat out on one big order. When the order stops, the machines keep costing money. MaxLinear sits in that spot right now. Revenue is up 43 percent, yet the company reports a 26 percent profit margin and negative 28 percent return on equity. At 37.7 times forward earnings the shares trade well above our fair value of 38.05 dollars against a current price of 71.84 dollars, a 47 percent gap that leaves no margin of safety.
We pass because the numbers do not support the price. This is a cyclical semiconductor business where peak earnings often arrive just before demand falls away. A low multiple can signal a bargain, yet a high multiple on still-loss-making results simply signals hope. Analyst targets sit at 60 dollars, but history shows these cycles reset faster than forecasts adjust.
The ethical screen clears, which removes one usual objection. Currency swings, customer concentration and sudden inventory corrections remain live threats that could widen the gap between price and value further. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MXL trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-22Distribution$77.11+0.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 24% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 24% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markup$77.11-1.4%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 24% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markup$78.18+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 24% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup$78.18+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 282% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markup$78.18+0.0%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 282% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markup$78.18-18.7%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 18.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 282% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markup$96.16+0.0%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 282% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markup$96.16+4.4%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 282% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58.
2026-10-02Markup · changed$92.12+38.8%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 38.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 282% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 474%. Our forward projection puts the odds of a 10% gain over the next month near 44%. The street (11 analysts) rates it buy, with a mean price target of $58. Since the last review it its composite score eased.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
